Sana Biotechnology (SANA) EBT (2020 - 2026)
Sana Biotechnology (SANA) posted EBT of -$162.4 million for Q1 2026, down 165.42% sequentially from -$61.2 million in Q4 2025, and up 25.17% YoY from -$129.8 million in Q1 2025.
Sana Biotechnology (SANA) EBT (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported EBT for 7 years, with the latest figure at -$162.4 million in Q1 2026.
- Quarterly EBT rose 25.17% year-over-year to -$162.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$534.9 million (up 16.4% YoY) and the FY2025 annual result came in at -$369.6 million, down 5.54% from the prior year.
- EBT retreated to -$162.4 million in Q1 2026 per SANA's latest filing, from -$61.2 million in the prior quarter.
- Over five years, EBT peaked at -$52.4 million in Q4 2024 and troughed at -$493.1 million in Q4 2023.
- A 5-year average of -$193.9 million and a median of -$196.7 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT sank 773.18% in 2022, then jumped 89.38% in 2024.
- Over 5 years, EBT stood at -$83.4 million in 2022, then plunged by 491.21% to -$493.1 million in 2023, then surged by 89.38% to -$52.4 million in 2024, then slipped by 16.82% to -$61.2 million in 2025, then sank by 165.42% to -$162.4 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$162.4 million, -$61.2 million, and -$86.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | -176.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -176.08 Mn |
| Mar 31, 2026 | -162.42 Mn |
| Dec 31, 2025 | -61.19 Mn |
| Sep 30, 2025 | -86.08 Mn |
| Jun 30, 2025 | -225.25 Mn |
| Mar 31, 2025 | -217.03 Mn |
| Dec 31, 2024 | -52.38 Mn |
| Sep 30, 2024 | -238.12 Mn |
| Jun 30, 2024 | -132.38 Mn |
| Mar 31, 2024 | -196.66 Mn |
| Dec 31, 2023 | -493.14 Mn |
| Sep 30, 2023 | -209.07 Mn |
| Jun 30, 2023 | -351.07 Mn |
| Mar 31, 2023 | -188.49 Mn |
| Dec 31, 2022 | -83.41 Mn |
| Sep 30, 2022 | -241.01 Mn |
| Jun 30, 2022 | -142.88 Mn |
| Mar 31, 2022 | -215.55 Mn |
| Dec 31, 2021 | -269.19 Mn |
| Sep 30, 2021 | -254.38 Mn |